Drug intelligence / Profile preview

pingvakatin

Development stage: Phase 1
Lead developer: Shanghai Institute of Materia Medica
Modality: Small Molecules
Administration: Oral

Overview

Pingvakatin (DC371739) is an orally bioavailable small molecule inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), developed by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. It is being investigated for the treatment of hypercholesterolemia and mixed dyslipidemia. By inhibiting PCSK9, the drug prevents the degradation of low-density lipoprotein receptors (LDLR) on the surface of liver cells, which enhances the liver's ability to clear LDL cholesterol from the bloodstream. As an oral agent, it offers a potential alternative to injectable PCSK9 monoclonal antibodies.

Other names: pingvakatin

Targets

HNF1A (Hepatocyte nuclear factor 1-alpha)ANGPTL3 (Angiopoietin-like protein 3)

Beyond the preview

Go deeper on pingvakatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pingvakatin.

Explore the full profile